Perspective examines DCAF16 recruitment beyond CRBN and VHL
Academic source · Journal of Medicinal Chemistry
Source published: · Event / reporting date: 2026-11-05
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What the paper reports
A Journal of Medicinal Chemistry perspective examines DCAF16-recruiting degraders, including recruiting motifs, structure–activity relationships, and structural design principles. The original abstract discusses bifunctional and monovalent approaches and highlights movement of programs such as PLX-61639 and AMX-883 toward clinical evaluation. This is a medicinal chemistry synthesis, not a new comparative clinical trial or proof of superiority.
Why this paper is included
Analysis: Alternative E3 recruitment may broaden degrader design options, but selectivity, resistance, tissue context, and clinical tolerability need program-specific evaluation.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections